ECSP20050785A - Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) - Google Patents
Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)Info
- Publication number
- ECSP20050785A ECSP20050785A ECSENADI202050785A ECDI202050785A ECSP20050785A EC SP20050785 A ECSP20050785 A EC SP20050785A EC SENADI202050785 A ECSENADI202050785 A EC SENADI202050785A EC DI202050785 A ECDI202050785 A EC DI202050785A EC SP20050785 A ECSP20050785 A EC SP20050785A
- Authority
- EC
- Ecuador
- Prior art keywords
- pyridin
- methyl
- ghrelin
- acyltransferase
- goat
- Prior art date
Links
- 102100038752 Ghrelin O-acyltransferase Human genes 0.000 title abstract 4
- 101710205760 Ghrelin O-acyltransferase Proteins 0.000 title abstract 4
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical group [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- RWXCVESEMJNNMF-UHFFFAOYSA-N oxadiazolo[5,4-b]pyridine Chemical group C1=CN=C2ON=NC2=C1 RWXCVESEMJNNMF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Obesity (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula general I, I en donde los grupos R1 y R2 se definen de acuerdo con la reivindicación 1, que tienen propiedades farmacológicas valiosas, en particular, se fijan a ghrelin O-aciltransferasa (GOAT) y modulan su actividad. Los compuestos son adecuados para el tratamiento y la prevención de enfermedades que se pueden ver influenciadas por este receptor, tales como enfermedades metabólicas, en particular, obesidad.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18154824 | 2018-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP20050785A true ECSP20050785A (es) | 2020-09-30 |
Family
ID=61157050
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202050785A ECSP20050785A (es) | 2018-02-02 | 2020-08-24 | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11254688B2 (es) |
| EP (1) | EP3746451B1 (es) |
| JP (1) | JP7015396B2 (es) |
| KR (1) | KR20200116978A (es) |
| CN (1) | CN111655700B (es) |
| AU (1) | AU2019215707A1 (es) |
| BR (1) | BR112020013082A2 (es) |
| CA (1) | CA3087826A1 (es) |
| CL (1) | CL2020001907A1 (es) |
| CO (1) | CO2020009299A2 (es) |
| CR (1) | CR20200332A (es) |
| EA (1) | EA202091805A1 (es) |
| EC (1) | ECSP20050785A (es) |
| IL (1) | IL276136A (es) |
| JO (1) | JOP20200190A1 (es) |
| MA (1) | MA53075A (es) |
| MX (1) | MX2020008053A (es) |
| PE (1) | PE20210174A1 (es) |
| PH (1) | PH12020551168A1 (es) |
| SG (1) | SG11202006125VA (es) |
| WO (1) | WO2019149657A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811804QA (en) * | 2016-08-05 | 2019-01-30 | Boehringer Ingelheim Int | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| AU2019215707A1 (en) | 2018-02-02 | 2020-07-09 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors |
| EP3746449B1 (en) * | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| TW202140440A (zh) | 2020-02-28 | 2021-11-01 | 美商克力歐普股份有限公司 | Gpr40激動劑 |
| WO2021233882A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| CN115916789B (zh) * | 2020-05-22 | 2025-06-27 | 勃林格殷格翰国际有限公司 | 制备烷基7-氨基-5-甲基-[1,2,5]噁二唑并[3,4-b]吡啶羧酸酯的连续方法 |
| WO2023114472A1 (en) * | 2021-12-16 | 2023-06-22 | Icahn School Of Medicine At Mount Sinai | Heterocyclic compounds as 5ht2a biased agonists |
| CN114426516B (zh) * | 2022-02-16 | 2022-11-04 | 安徽有吉医药科技有限公司 | 一种2-氨基-3-溴吡啶的制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004082383A1 (en) | 2003-03-17 | 2004-09-30 | Basf Aktiengesellschaft | Use of triazolopyrimidines for combating nematode diseases of plants |
| US20090253673A1 (en) * | 2006-07-12 | 2009-10-08 | Min Ge | Substituted Pyrazoles as Ghrelin Receptor Antagonists |
| CA2677932A1 (en) | 2007-02-15 | 2008-08-21 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| CN101720323A (zh) | 2007-04-11 | 2010-06-02 | 三井有限公司 | 具有抗癌活性的化合物 |
| EP2152672A1 (en) | 2007-05-24 | 2010-02-17 | Bayer Schering Pharma Aktiengesellschaft | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| FR2934058B1 (fr) | 2008-07-15 | 2010-09-24 | Centre Nat Rech Scient | Dispositif de projection interferometrique a trois ouvertures pour produire une tache constituee de structures fines |
| FR2933989B1 (fr) | 2008-07-16 | 2013-03-08 | Commissariat Energie Atomique | Procede de purification de microorganismes presents dans des echantillons liquides |
| FR2933975B1 (fr) | 2008-07-17 | 2011-02-18 | Servier Lab | Nouveau procede de preparation de benzocyclobutenes fonctionnalises,et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable. |
| EP2370462B1 (en) | 2008-12-15 | 2014-07-16 | Zealand Pharma A/S | Glucagon analogues |
| CN102282167B (zh) | 2008-12-15 | 2014-08-13 | 西兰制药公司 | 胰高血糖素类似物 |
| JP5635531B2 (ja) | 2008-12-15 | 2014-12-03 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
| AU2010272944B2 (en) | 2009-07-13 | 2015-11-19 | Zealand Pharma A/S | Acylated glucagon analogues |
| US20110078154A1 (en) | 2009-09-28 | 2011-03-31 | Accenture Global Services Gmbh | Recruitment screening tool |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| IN2014CN04401A (es) | 2011-12-23 | 2015-09-04 | Zealand Pharma As | |
| US9238639B2 (en) | 2012-02-24 | 2016-01-19 | Takeda Pharmaceutical Company Limited | Aromatic ring compound |
| EP2863910B1 (en) | 2012-06-20 | 2020-03-11 | University Of Virginia Patent Foundation | Compositions and methods for regulating glucose homeostasis and insulin action |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA118034C2 (uk) * | 2013-11-14 | 2018-11-12 | Елі Ліллі Енд Компані | Заміщений піперидилетилпіримідин як інгібітор грелін-o-ацилтрансферази |
| EP3193939A4 (en) | 2014-09-17 | 2018-10-24 | The Regents of The University of California | Small lipopeptidomimetic inhibitors of ghrelin o-acyl transferase |
| WO2016123275A1 (en) | 2015-01-30 | 2016-08-04 | Boehringer Ingelheim International Gmbh | Aldosterone synthase inhibitors |
| AR104672A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| AR104673A1 (es) | 2015-04-15 | 2017-08-09 | Lilly Co Eli | Inhibidores de grelina o-aciltransferasa |
| DK3364993T3 (da) * | 2015-10-22 | 2023-01-09 | Cavion Inc | Fremgangsmåder til behandling af angelman syndrom |
| SG11201811804QA (en) * | 2016-08-05 | 2019-01-30 | Boehringer Ingelheim Int | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
| SG11201900588YA (en) * | 2016-08-11 | 2019-02-27 | Cellix Bio Private Ltd | Compositions and methods for the treatment of irritable bowel syndrome |
| EP3504185B1 (en) | 2016-08-29 | 2021-11-24 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| WO2019149659A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| EP3746449B1 (en) | 2018-02-02 | 2022-03-30 | Boehringer Ingelheim International GmbH | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| AU2019215707A1 (en) | 2018-02-02 | 2020-07-09 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
-
2019
- 2019-01-28 AU AU2019215707A patent/AU2019215707A1/en not_active Abandoned
- 2019-01-28 SG SG11202006125VA patent/SG11202006125VA/en unknown
- 2019-01-28 BR BR112020013082-6A patent/BR112020013082A2/pt not_active Application Discontinuation
- 2019-01-28 MA MA053075A patent/MA53075A/fr unknown
- 2019-01-28 CR CR20200332A patent/CR20200332A/es unknown
- 2019-01-28 EA EA202091805A patent/EA202091805A1/ru unknown
- 2019-01-28 US US16/966,483 patent/US11254688B2/en active Active
- 2019-01-28 EP EP19702246.0A patent/EP3746451B1/en active Active
- 2019-01-28 MX MX2020008053A patent/MX2020008053A/es unknown
- 2019-01-28 KR KR1020207025417A patent/KR20200116978A/ko not_active Withdrawn
- 2019-01-28 JP JP2020541873A patent/JP7015396B2/ja active Active
- 2019-01-28 WO PCT/EP2019/051989 patent/WO2019149657A1/en not_active Ceased
- 2019-01-28 CN CN201980010416.2A patent/CN111655700B/zh active Active
- 2019-01-28 CA CA3087826A patent/CA3087826A1/en not_active Abandoned
- 2019-01-28 PE PE2020001161A patent/PE20210174A1/es unknown
- 2019-01-28 JO JOP/2020/0190A patent/JOP20200190A1/ar unknown
-
2020
- 2020-07-19 IL IL276136A patent/IL276136A/en unknown
- 2020-07-21 CL CL2020001907A patent/CL2020001907A1/es unknown
- 2020-07-28 CO CONC2020/0009299A patent/CO2020009299A2/es unknown
- 2020-07-31 PH PH12020551168A patent/PH12020551168A1/en unknown
- 2020-08-24 EC ECSENADI202050785A patent/ECSP20050785A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2020009299A2 (es) | 2020-08-21 |
| WO2019149657A1 (en) | 2019-08-08 |
| US20210053985A1 (en) | 2021-02-25 |
| PH12020551168A1 (en) | 2021-05-31 |
| EP3746451B1 (en) | 2023-07-12 |
| JP2021512113A (ja) | 2021-05-13 |
| EP3746451A1 (en) | 2020-12-09 |
| JOP20200190A1 (ar) | 2020-07-29 |
| CR20200332A (es) | 2020-09-03 |
| CN111655700A (zh) | 2020-09-11 |
| SG11202006125VA (en) | 2020-07-29 |
| US11254688B2 (en) | 2022-02-22 |
| CN111655700B (zh) | 2023-07-18 |
| JP7015396B2 (ja) | 2022-02-15 |
| AU2019215707A1 (en) | 2020-07-09 |
| EA202091805A1 (ru) | 2020-12-16 |
| IL276136A (en) | 2020-09-30 |
| PE20210174A1 (es) | 2021-01-29 |
| CA3087826A1 (en) | 2019-08-08 |
| MA53075A (fr) | 2021-05-12 |
| BR112020013082A2 (pt) | 2020-12-01 |
| KR20200116978A (ko) | 2020-10-13 |
| MX2020008053A (es) | 2020-09-07 |
| CL2020001907A1 (es) | 2020-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20050785A (es) | Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050797A (es) | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| CO2019000601A2 (es) | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP20050791A (es) | Derivados de oxadiazolopiridina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltransferasa (goat) | |
| ECSP24026455A (es) | Compuestos de pirrolotriazina como inhibidores de tam | |
| CO2018008173A2 (es) | Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock) | |
| MX2022014648A (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| ECSP17073191A (es) | Compuestos heterocíclicos como inhibidores de lsd1 | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| MX2017000485A (es) | Espirocicloheptanos como inhibidores de la cinasa rho (rock). | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| CR20190232A (es) | DERIVADOS DE TIOHIDANTOÍNA SUSTITUÍDOS COMO ANTAGONISTAS DEL RECEPTOR DE ANDRÓGENOS (divisional 2018-0352) | |
| UY35312A (es) | Ácidos indaniloxidihidrobenzofuranilacéticos como agonistas del receptor acoplado a la proteína g40 | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| NI201400043A (es) | 4 - fenil - piridinas sustituidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| MX2019004030A (es) | Inhibidores del receptor de glucocorticoides. | |
| UY35668A (es) | Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen | |
| NI201801172A (es) | Nuevos compuestos para el tratamiento de enfermedades parasitarias | |
| CL2020001461A1 (es) | Inhibidores de dopamina–b–hidroxilasa. |